Asset profile

CPT31

Peptide

Phase 1HIV gp41No recent registered activity
Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page
Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

Competitive landscape

60 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 57 same-indication; 49 further along in development.

Unlock with Research ↗
DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
CPT31: this drugPhase 1PeptideHIV gp41
Albuvirtide (Aikening)Phase 3PeptideHIV gp41
LipovirtidePhase 2PeptideHIV gp41
LP-98Phase 1/2PeptideHIV gp41
Bictegravir (Biktarvy)ApprovedSmall moleculeHIV integrase
Cabotegravir (Vocabria / Cabenuva / Apretude)ApprovedSmall moleculeHIV integrase
Crofelemer (Mytesi)ApprovedSmall moleculeChloride channel (intestinal epithelium)
Darunavir (Prezista)ApprovedSmall moleculeHIV protease
Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component))ApprovedSmall moleculeHIV integrase
Doravirine (Pifeltro)ApprovedSmall moleculeHIV reverse transcriptase
Elsulfavirine (Elpida)ApprovedSmall moleculeHIV reverse transcriptase
Elvitegravir (Stribild / Genvoya (component))ApprovedSmall moleculeHIV integrase
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada)ApprovedSmall moleculeHIV reverse transcriptase
Etravirine (Intelence)ApprovedSmall moleculeHIV reverse transcriptase
Fosamprenavir (Lexiva / Telzir)ApprovedSmall moleculeHIV protease
Fostemsavir (Rukobia)ApprovedSmall moleculeHIV gp120

…and 45 more. Research shows the complete landscape.

Research

Unlock the full comparison

Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.

Upcoming events

No upcoming readouts on record for this asset.

All registered studies

Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.